阿托伐他汀联合曲美他嗪治疗冠心病的临床效果评价(1)
摘 要：目的 分析阿托伐他汀+曲美他嗪治疗冠心病的临床疗效。方法 选取2016年1月～2017年12月来我院就诊的86例冠心病患者，随机分为对照组和研究组，每组43例。两组患者均接受常规治疗，对照组在此基础上服用盐酸曲美他嗪片，研究组服用阿托伐他汀钙片+盐酸曲美他嗪片，观察两组患者治疗总有效率、血脂指标、常规指标及不良反应的发生情况。结果 研究组治疗总有效率为93.02%，高于对照组的76.74%，差异具有统计学意义(P<0.05)。研究组血脂指标及常规指标优于对照组，差异有统计学意义(P<0.05)。研究组不良反应发生率为4.65%，低于对照组的18.60%，差异有统计学意义(P<0.05)。结论 阿托伐他汀联合曲美他嗪治疗冠心病疗效显著，安全性高，值得推广应用。
关键词：冠心病；阿托伐他汀；曲美他嗪
中图分类号：R541.4 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.13.041
, http://www.100md.com
文章编号：1006-1959(2018)13-0139-03
Abstract：Objective To analyze the clinical efficacy of Atto vastatin combined with trimetazidine in the treatment of coronary atherosclerotic heart disease.Methods 86 patients with coronary atherosclerotic heart disease from January 2016 to December 2017 were randomly divided into control group(n=43)and study group(n=43).Patients in both groups received routine treatment，the control group took trimetazidine hydrochloride tablets on this basis，and the study group took Atto vastatin calcium+trimetazidine hydrochloride tablets.The total effective rate and blood lipid index of the two groups were observed as well as routine indicators and adverse reactions.Results The total effective rate of the study group was 93.02%，which was higher than that of the control group 76.74%，the difference was statistically significant(P<0.05).The blood lipid index and routine index in the study group were better than those in the control group，and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the study group was 4.65%，which was significantly lower than that in the control group 18.60%，the difference was statistically significant(P<0.05).Conclusion Atto vastatin combined with trimetazidine is effective and safe in the treatment of coronary atherosclerotic heart disease.
, 百拇医药
Key words：Coronary atherosclerotic heart disease；Atto vastatin；Trimetazidine
冠状动脉性心脏病(coronary atherosclerotic heart disease)简称“冠心病”，是因冠状动脉血管发生动脉粥样硬化病变引发的血管腔狭窄或阻塞，世界卫生组织将冠心病分为隐匿性冠心病、心肌梗死、心绞痛、缺血性心脏病及猝死五种，临床常将其分为稳定性冠心病和急性冠状动脉综合征，中老年人、烟民、糖尿病及高血压患者是该病高发群体，患者多伴有突发心前区疼痛、胸部闷胀感、呼吸短促、晕眩、恶心等症状，严重影响其劳动能力及生活质量，若不及时医治将危及生命[1]。阿托伐他汀和曲美他嗪均为冠心病患者临床常用药物，均可有效缓解临床症状，为提高治疗治疗安全性和有效率，近年来联合用药较为多见。本文旨在分析阿托伐他汀联合曲美他嗪治疗冠心病的临床疗效，现报道如下。
1资料与方法
1.1一般资料 选取2016年1月～2017年12月蕲春县人民医院心血管内科收治的冠心病患者86例，以随机数字表法分为研究组和对照组，每组43例。所有入选对象均同意参与研究，且符合WHO制定的冠心病诊断标准[2]，排除药物过敏、合并其它重大疾病(肝肾功能不全、免疫系统疾病)及精神交流障碍者。研究组男23例，女20例；年龄44～72岁，平均年龄(53.46±3.47)岁；病程1～10年，平均病程(7.64±1.25)年。对照组男25例，女18例；年齡46～73岁，平均年龄(53.42±3.56)岁；病程2～11年，平均病程(7.51±1.22)年。患者均伴有心前区不适、典型胸痛、心悸、呕吐、心力衰竭等症状。两组患者性别、年龄、病程等基本资料对比，差异无统计学意义(P>0.05)，可用以对比分析。, http://www.100md.com(王毅)
关键词：冠心病；阿托伐他汀；曲美他嗪
中图分类号：R541.4 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.13.041
, http://www.100md.com
文章编号：1006-1959(2018)13-0139-03
Abstract：Objective To analyze the clinical efficacy of Atto vastatin combined with trimetazidine in the treatment of coronary atherosclerotic heart disease.Methods 86 patients with coronary atherosclerotic heart disease from January 2016 to December 2017 were randomly divided into control group(n=43)and study group(n=43).Patients in both groups received routine treatment，the control group took trimetazidine hydrochloride tablets on this basis，and the study group took Atto vastatin calcium+trimetazidine hydrochloride tablets.The total effective rate and blood lipid index of the two groups were observed as well as routine indicators and adverse reactions.Results The total effective rate of the study group was 93.02%，which was higher than that of the control group 76.74%，the difference was statistically significant(P<0.05).The blood lipid index and routine index in the study group were better than those in the control group，and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the study group was 4.65%，which was significantly lower than that in the control group 18.60%，the difference was statistically significant(P<0.05).Conclusion Atto vastatin combined with trimetazidine is effective and safe in the treatment of coronary atherosclerotic heart disease.
, 百拇医药
Key words：Coronary atherosclerotic heart disease；Atto vastatin；Trimetazidine
冠状动脉性心脏病(coronary atherosclerotic heart disease)简称“冠心病”，是因冠状动脉血管发生动脉粥样硬化病变引发的血管腔狭窄或阻塞，世界卫生组织将冠心病分为隐匿性冠心病、心肌梗死、心绞痛、缺血性心脏病及猝死五种，临床常将其分为稳定性冠心病和急性冠状动脉综合征，中老年人、烟民、糖尿病及高血压患者是该病高发群体，患者多伴有突发心前区疼痛、胸部闷胀感、呼吸短促、晕眩、恶心等症状，严重影响其劳动能力及生活质量，若不及时医治将危及生命[1]。阿托伐他汀和曲美他嗪均为冠心病患者临床常用药物，均可有效缓解临床症状，为提高治疗治疗安全性和有效率，近年来联合用药较为多见。本文旨在分析阿托伐他汀联合曲美他嗪治疗冠心病的临床疗效，现报道如下。
1资料与方法
1.1一般资料 选取2016年1月～2017年12月蕲春县人民医院心血管内科收治的冠心病患者86例，以随机数字表法分为研究组和对照组，每组43例。所有入选对象均同意参与研究，且符合WHO制定的冠心病诊断标准[2]，排除药物过敏、合并其它重大疾病(肝肾功能不全、免疫系统疾病)及精神交流障碍者。研究组男23例，女20例；年龄44～72岁，平均年龄(53.46±3.47)岁；病程1～10年，平均病程(7.64±1.25)年。对照组男25例，女18例；年齡46～73岁，平均年龄(53.42±3.56)岁；病程2～11年，平均病程(7.51±1.22)年。患者均伴有心前区不适、典型胸痛、心悸、呕吐、心力衰竭等症状。两组患者性别、年龄、病程等基本资料对比，差异无统计学意义(P>0.05)，可用以对比分析。, http://www.100md.com(王毅)